|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,951.50 INR | +0.46% |
|
+2.53% | +13.48% |
| 08:34pm | India's Sun Pharma wins South Africa approval to launch generic Ozempic | RE |
| 11:23am | Sun Pharma Wins South Africa Approval for Generic Semaglutide | MT |
| Market Cap | 4,68200Cr 4.87TCr 4.25TCr 3.92TCr 3.61TCr 6.84TCr 6.95TCr 47TCr 18TCr 2,28900Cr 18TCr 18TCr 7,88800Cr | P/E 2027 * |
35.6x | P/E 2028 * | 30.2x |
|---|---|---|---|---|---|
| Enterprise Value | 4,40900Cr 4.58TCr 4.01TCr 3.7TCr 3.4TCr 6.44TCr 6.55TCr 44TCr 17TCr 2,15500Cr 17TCr 17TCr 7,42800Cr | EV / Sales 2027 * |
6.74x | EV / Sales 2028 * | 5.95x |
| Free-Float |
44.39% | Yield 2027 * |
0.81% | Yield 2028 * | 0.91% |
Last Transcript: Sun Pharmaceutical Industries Ltd.
| 1 day | +0.46% | ||
| 1 week | +2.53% | ||
| Current month | +4.78% | ||
| 1 month | +7.95% | ||
| 3 months | +18.12% | ||
| 6 months | +14.75% | ||
| Current year | +13.48% |
| 1 week | 1,888.2 |  | 1,962.7 |
| 1 month | 1,792.6 | | 1,962.7 |
| Current year | 1,583.7 | | 1,962.7 |
| 1 year | 1,548 | | 1,962.7 |
| 3 years | 1,063.85 | | 1,962.7 |
| 5 years | 672.55 | | 1,962.7 |
| 10 years | 312 | | 1,962.7 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Chief Executive Officer | 59 | 01/09/2025 | |
| Director of Finance/CFO | 58 | 01/07/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 59 | 01/09/2025 | |
| Director/Board Member | 73 | 25/05/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.46% | +2.53% | +15.98% | +81.88% | 4.85TCr | |
| -0.36% | -4.82% | +65.56% | +115.03% | 3.57TCr | |
| -0.01% | -0.95% | -3.10% | +39.49% | 1.21TCr | |
| +2.06% | +0.34% | +19.46% | +94.32% | 1.18TCr | |
| +1.13% | +0.38% | +32.83% | +126.50% | 918.79Cr | |
| -1.81% | -2.85% | +45.77% | -5.83% | 705.8Cr | |
| -0.17% | 0.00% | +18.91% | +37.57% | 701Cr | |
| -0.33% | +1.43% | +3.52% | +227.22% | 677.23Cr | |
| +6.39% | -0.15% | -14.91% | +20.63% | 597.99Cr | |
| +1.33% | +4.21% | +30.52% | +139.19% | 443.21Cr | |
| Average | +0.87% | +0.66% | +21.46% | +87.60% | 1.49TCr | |
| Weighted average by Cap. | +0.48% | -0.17% | +27.83% | +89.75% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 65TCr 679.77Cr 594.32Cr 548.25Cr 503.98Cr 954.93Cr 971.26Cr 6.55TCr 2.57TCr 32TCr 2.55TCr 2.5TCr 1,10200Cr | 73TCr 757.99Cr 662.71Cr 611.34Cr 561.98Cr 1.06TCr 1.08TCr 7.3TCr 2.86TCr 36TCr 2.85TCr 2.78TCr 1,22900Cr |
| Net income | 13TCr 137.8Cr 120.48Cr 111.14Cr 102.16Cr 193.58Cr 196.89Cr 1.33TCr 520.6Cr 6.48TCr 517.49Cr 506.15Cr 22TCr | 16TCr 162.71Cr 142.26Cr 131.23Cr 120.64Cr 228.58Cr 232.49Cr 1.57TCr 614.73Cr 7.65TCr 611.05Cr 597.66Cr 26TCr |
| Net Debt | -27TCr -283.96Cr -248.26Cr -229.02Cr -210.52Cr -398.89Cr -405.72Cr -2.73TCr -1.07TCr -13TCr -1.07TCr -1.04TCr -46TCr | -34TCr -354.88Cr -310.27Cr -286.22Cr -263.11Cr -498.53Cr -507.05Cr -3.42TCr -1.34TCr -17TCr -1.33TCr -1.3TCr -58TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/26/15 | ₹1,951.50 | +0.46% | 22,83,494 |
| 14/26/14 | ₹1,942.60 | +1.10% | 28,22,124 |
| 13/26/13 | ₹1,921.40 | -0.73% | 15,73,176 |
| 10/26/10 | ₹1,935.50 | -0.17% | 14,78,172 |
| 09/26/09 | ₹1,938.70 | +2.67% | 44,46,201 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SUNPHARMA Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition